/ADYX
ADYX Stock - Adynxx, Inc.
Healthcare|BiotechnologyOTC
$0.00+0.00%
+$0.00 (+0.00%) • Dec 19
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.31
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ADYX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-7.74
52W High$0.00
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|
| Revenue | $2.22M | $2.02M | $16.29M | $15.04M | $4.79M |
| Gross Profit | $496,000 | $178,000 | $9.64M | $7.67M | $1.52M |
| Gross Margin | 22.4% | 8.8% | 59.2% | 51.0% | 31.7% |
| Operating Income | $-5,296,000 | $-4,760,000 | $-31,188,000 | $-28,305,987 | $-25,418,400 |
| Net Income | $-8,417,000 | $-25,707,000 | $-28,243,000 | $-26,017,000 | $-25,445,435 |
| Net Margin | -379.8% | -1273.3% | -173.3% | -173.0% | -531.6% |
| EPS | $-10.26 | $-35.94 | $-60.60 | $-67.69 | $-104.36 |
Company Overview
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ADYXBeat Rate
31%
Last 13 quarters
Avg Surprise
-19.0%
EPS vs Estimate
Beats / Misses
4/9
Last 12 quarters
Latest EPS
$-0.33
Q4 2019
EPS Surprise History
Q1 18
-268.8%
$-15.60vs$-4.23
Q2 18
No data
Q3 18
No data
Q4 18
No data
Q1 19
No data
Q2 19
No data
Q3 19
No data
Q4 19
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2019 | Nov 14, 2019 | — | $-0.33 | — | — |
Q3 2019 | Aug 14, 2019 | — | $-0.86 | — | — |
Q2 2019 | Apr 23, 2019 | — | $-1.32 | — | — |
Q1 2019 | Feb 22, 2019 | — | $-1.55 | — | — |
Q4 2018 | Oct 26, 2018 | — | $-0.91 | — | — |
Q3 2018 | Aug 10, 2018 | — | $-1.72 | — | — |
Q2 2018 | May 14, 2018 | — | $-7.13 | — | — |
Q1 2018 | Mar 2, 2018 | $-4.23 | $-15.60 | -268.8% | ✗ MISS |
Q4 2017 | Nov 9, 2017 | $-1.80 | $-3.36 | -86.7% | ✗ MISS |
Q3 2017 | Aug 10, 2017 | $-8.40 | $-5.40 | +35.7% | ✓ BEAT |
Q2 2017 | May 9, 2017 | $-11.70 | $-12.00 | -2.6% | ✗ MISS |
Q1 2017 | Mar 7, 2017 | $-11.40 | $-13.20 | -15.8% | ✗ MISS |
Q4 2016 | Nov 4, 2016 | $-14.55 | $-15.60 | -7.2% | ✗ MISS |
Q3 2016 | Aug 9, 2016 | $-16.08 | $3.00 | +118.7% | ✓ BEAT |
Q2 2016 | May 10, 2016 | $-14.88 | $-16.80 | -12.9% | ✗ MISS |
Q1 2016 | Feb 23, 2016 | $-16.68 | $-9.60 | +42.4% | ✓ BEAT |
Q4 2015 | Nov 5, 2015 | $-16.50 | $-15.60 | +5.5% | ✓ BEAT |
Q3 2015 | Aug 6, 2015 | $-18.12 | $-19.20 | -6.0% | ✗ MISS |
Q2 2015 | May 14, 2015 | $-20.88 | $-28.80 | -37.9% | ✗ MISS |
Q1 2015 | Feb 24, 2015 | $-18.30 | $-20.40 | -11.5% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about ADYX
What is ADYX's current stock price?
Adynxx, Inc. (ADYX) is currently trading at $0.00 per share. The stock has moved +0.00% today.
What is the analyst price target for ADYX?
No analyst price targets are currently available for this stock.
What sector is Adynxx, Inc. in?
Adynxx, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ADYX's market cap?
Adynxx, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ADYX pay dividends?
No, Adynxx, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBGMD
BG Medicine, Inc.
$0.00
Mkt Cap: $0.0B
BIMI
BIMI International Medical Inc.
$0.00
Mkt Cap: $0.0B
BNKL
Bionik Laboratories Corp.
$0.00
Mkt Cap: $0.0B
CFRXQ
ContraFect Corporation
$0.00
Mkt Cap: $0.0B
EFTR
eFFECTOR Therapeutics, Inc.
$0.00
Mkt Cap: $0.0B
FSPM
FusionPharm, Inc.
$0.00
Mkt Cap: $0.0B
IMVIF
IMV Inc.
$0.00
Mkt Cap: $0.0B
MILC
Millennium Sustainable Ventures Corp.
$0.00
Mkt Cap: $0.0B
NMTRQ
9 Meters Biopharma, Inc.
$0.00
Mkt Cap: $0.0B
OMMH
Omnimmune Holdings, Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to ADYX for comparison